ASX Share rice
Thu 06 Aug 2020 - 12:12:am (Sydney)

PAR Share Price

PARADIGM BIOPHARMACEUTICALS LIMITED..PARPharmaceuticals, Biotechnology & Life Sciences

PAR Company Information

Name:

Paradigm Biopharmaceuticals Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

500 Collins Street Melbourne VIC Australia 3000

Phone:

61 3 9629 5566

CEO, MD & Interim Exec. Chairman:

Mr. Paul Rennie B.Sc., BSc, Grad Dip, MBM, MSTC

CFO & Company Sec.:

Mr. Kevin G. Hollingsworth

Chief Operating Officer:

Dr. Jeannette Joughin

Chief Scientific Officer:

Dr. Ravi Krishnan

Director of Investor Relations:

Simon White

Company Overview:

Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable and tablet forms for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

PAR Share Price Information

Shares Issued:

226.96M

Market Capitalisation:

$676.35M

Revenue (TTM):

$3.78M

Revenue Per Share (TTM):

$0.02

Earnings per Share:

$-0.109

Operating Margin (TTM):

$-2.55

Return On Assets (TTM):

$-0.12

Return On Equity (TTM):

$-0.33

Quarterly Revenue Growth (YOY):

28.352

Gross Profit(TTM):

$2.98M

Diluted Earnings Per Share (TTM):

$-0.096

PAR CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-6,521,979

Change To Liabilities:

$1.13M

Total Cashflow From Investing Activities:

$-6,521,979

Net Income:

$-15,627,544

Total Cash From Operating Activities:

$-6,365,095

Depreciation:

$8.35K

Change To Account Receivables:

$-797,448

Sale Purchase Of Stock:

$-5,269,719

Capital Expenditures:

$21.98K

PAR Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-15,627,544

Net Income:

$-15,627,544

Gross Profit:

$2.98M

Operating Income:

$-10,215,225

Other Operating Expenses:

$213.17K

Total Revenue:

$2.98M

Total Operating Expenses:

$10.22M

PAR Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$2.98M

Total Liabilities:

$2.70M

Total Stockholder Equity:

$82.81M

Total Assets:

$85.51M

Common Stock:

$109.47M

Retained Earnings:

$-30,734,818

Cash:

$72.34M

Total Current Liabilities:

$2.70M

Property - Plant & Equipment:

$24.03K

Net Tangible Assets:

$79.82M

Total Current Assets:

$82.51M

Net Receivables:

$3.53M

Short-Term Investments:

$3.01M

Accounts Payable:

$2.28M

Non Currrent Assets (Other):

$3.01M

Short-Term Investments:

$3.01

Non Current Liabilities Total:

$0

PAR Share Price History

PAR News

24 Mar, 2020
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March ...
13 Mar, 2020
It certainly might concern Paradigm Biopharmaceuticals Limited (ASX:PAR) shareholders to see the share price down 51...
11 Dec, 2019
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Paradigm...
04 Nov, 2019
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
04 Oct, 2019
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Mistakes are...
08 Aug, 2019
Every investor in Paradigm Biopharmaceuticals Limited (ASX:PAR) should be aware of the most powerful shareholder...